Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...